Management of accidental exposure to Ebola virus in the biosafety Level 4 Laboratory, Hamburg, Germany

Stephan Günther, Heinz Feldmann, Thomas Geisbert, Lisa E. Hensley, Pierre E. Rollin, Stuart T. Nichol, Ute Ströher, Harvey Artsob, Clarence J. Peters, Thomas Ksiazek, Stephan Becker, Jan Ter Meulen, Stephan Ölschläger, Jonas Schmidt-Chanasit, Hinrich Sudeck, Gerd D. Burchard, Stefan Schmiedel

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

A needlestick injury occurred during an animal experiment in the biosafety level 4 laboratory in Hamburg, Germany, in March 2009. The syringe contained Zaire ebolavirus (ZEBOV) mixed with Freund's adjuvant. Neither an approved treatment nor a postexposure prophylaxis (PEP) exists for Ebola hemorrhagic fever. Following a risk-benefit assessment, it was recommended the exposed person take an experimental vaccine that had shown PEP efficacy in ZEBOV-infected nonhuman primates (NHPs) [12]. The vaccine, which had not been used previously in humans, was a live-attenuated recombinant vesicular stomatitis virus (recVSV) expressing the glycoprotein of ZEBOV. A single dose of 5 × 10 7 plaque-forming units was injected 48 hours after the accident. The vaccinee developed fever 12 hours later and recVSV viremia was detectable by polymerase chain reaction (PCR) for 2 days. Otherwise, the person remained healthy, and ZEBOV RNA, except for the glycoprotein gene expressed in the vaccine, was never detected in serum and peripheral blood mononuclear cells during the 3-week observation period.

Original languageEnglish (US)
JournalJournal of Infectious Diseases
Volume204
Issue numberSUPPL. 3
DOIs
StatePublished - Nov 1 2011

Fingerprint

Ebolavirus
Democratic Republic of the Congo
Germany
Vesicular Stomatitis
Vaccines
Glycoproteins
Ebola Hemorrhagic Fever
Viruses
Needlestick Injuries
Freund's Adjuvant
Viremia
Syringes
Primates
Accidents
Blood Cells
Fever
Observation
RNA
Polymerase Chain Reaction
Serum

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Management of accidental exposure to Ebola virus in the biosafety Level 4 Laboratory, Hamburg, Germany. / Günther, Stephan; Feldmann, Heinz; Geisbert, Thomas; Hensley, Lisa E.; Rollin, Pierre E.; Nichol, Stuart T.; Ströher, Ute; Artsob, Harvey; Peters, Clarence J.; Ksiazek, Thomas; Becker, Stephan; Ter Meulen, Jan; Ölschläger, Stephan; Schmidt-Chanasit, Jonas; Sudeck, Hinrich; Burchard, Gerd D.; Schmiedel, Stefan.

In: Journal of Infectious Diseases, Vol. 204, No. SUPPL. 3, 01.11.2011.

Research output: Contribution to journalArticle

Günther, S, Feldmann, H, Geisbert, T, Hensley, LE, Rollin, PE, Nichol, ST, Ströher, U, Artsob, H, Peters, CJ, Ksiazek, T, Becker, S, Ter Meulen, J, Ölschläger, S, Schmidt-Chanasit, J, Sudeck, H, Burchard, GD & Schmiedel, S 2011, 'Management of accidental exposure to Ebola virus in the biosafety Level 4 Laboratory, Hamburg, Germany', Journal of Infectious Diseases, vol. 204, no. SUPPL. 3. https://doi.org/10.1093/infdis/jir298
Günther, Stephan ; Feldmann, Heinz ; Geisbert, Thomas ; Hensley, Lisa E. ; Rollin, Pierre E. ; Nichol, Stuart T. ; Ströher, Ute ; Artsob, Harvey ; Peters, Clarence J. ; Ksiazek, Thomas ; Becker, Stephan ; Ter Meulen, Jan ; Ölschläger, Stephan ; Schmidt-Chanasit, Jonas ; Sudeck, Hinrich ; Burchard, Gerd D. ; Schmiedel, Stefan. / Management of accidental exposure to Ebola virus in the biosafety Level 4 Laboratory, Hamburg, Germany. In: Journal of Infectious Diseases. 2011 ; Vol. 204, No. SUPPL. 3.
@article{bfaf92dc2d1e429da478291781d0240d,
title = "Management of accidental exposure to Ebola virus in the biosafety Level 4 Laboratory, Hamburg, Germany",
abstract = "A needlestick injury occurred during an animal experiment in the biosafety level 4 laboratory in Hamburg, Germany, in March 2009. The syringe contained Zaire ebolavirus (ZEBOV) mixed with Freund's adjuvant. Neither an approved treatment nor a postexposure prophylaxis (PEP) exists for Ebola hemorrhagic fever. Following a risk-benefit assessment, it was recommended the exposed person take an experimental vaccine that had shown PEP efficacy in ZEBOV-infected nonhuman primates (NHPs) [12]. The vaccine, which had not been used previously in humans, was a live-attenuated recombinant vesicular stomatitis virus (recVSV) expressing the glycoprotein of ZEBOV. A single dose of 5 × 10 7 plaque-forming units was injected 48 hours after the accident. The vaccinee developed fever 12 hours later and recVSV viremia was detectable by polymerase chain reaction (PCR) for 2 days. Otherwise, the person remained healthy, and ZEBOV RNA, except for the glycoprotein gene expressed in the vaccine, was never detected in serum and peripheral blood mononuclear cells during the 3-week observation period.",
author = "Stephan G{\"u}nther and Heinz Feldmann and Thomas Geisbert and Hensley, {Lisa E.} and Rollin, {Pierre E.} and Nichol, {Stuart T.} and Ute Str{\"o}her and Harvey Artsob and Peters, {Clarence J.} and Thomas Ksiazek and Stephan Becker and {Ter Meulen}, Jan and Stephan {\"O}lschl{\"a}ger and Jonas Schmidt-Chanasit and Hinrich Sudeck and Burchard, {Gerd D.} and Stefan Schmiedel",
year = "2011",
month = "11",
day = "1",
doi = "10.1093/infdis/jir298",
language = "English (US)",
volume = "204",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Management of accidental exposure to Ebola virus in the biosafety Level 4 Laboratory, Hamburg, Germany

AU - Günther, Stephan

AU - Feldmann, Heinz

AU - Geisbert, Thomas

AU - Hensley, Lisa E.

AU - Rollin, Pierre E.

AU - Nichol, Stuart T.

AU - Ströher, Ute

AU - Artsob, Harvey

AU - Peters, Clarence J.

AU - Ksiazek, Thomas

AU - Becker, Stephan

AU - Ter Meulen, Jan

AU - Ölschläger, Stephan

AU - Schmidt-Chanasit, Jonas

AU - Sudeck, Hinrich

AU - Burchard, Gerd D.

AU - Schmiedel, Stefan

PY - 2011/11/1

Y1 - 2011/11/1

N2 - A needlestick injury occurred during an animal experiment in the biosafety level 4 laboratory in Hamburg, Germany, in March 2009. The syringe contained Zaire ebolavirus (ZEBOV) mixed with Freund's adjuvant. Neither an approved treatment nor a postexposure prophylaxis (PEP) exists for Ebola hemorrhagic fever. Following a risk-benefit assessment, it was recommended the exposed person take an experimental vaccine that had shown PEP efficacy in ZEBOV-infected nonhuman primates (NHPs) [12]. The vaccine, which had not been used previously in humans, was a live-attenuated recombinant vesicular stomatitis virus (recVSV) expressing the glycoprotein of ZEBOV. A single dose of 5 × 10 7 plaque-forming units was injected 48 hours after the accident. The vaccinee developed fever 12 hours later and recVSV viremia was detectable by polymerase chain reaction (PCR) for 2 days. Otherwise, the person remained healthy, and ZEBOV RNA, except for the glycoprotein gene expressed in the vaccine, was never detected in serum and peripheral blood mononuclear cells during the 3-week observation period.

AB - A needlestick injury occurred during an animal experiment in the biosafety level 4 laboratory in Hamburg, Germany, in March 2009. The syringe contained Zaire ebolavirus (ZEBOV) mixed with Freund's adjuvant. Neither an approved treatment nor a postexposure prophylaxis (PEP) exists for Ebola hemorrhagic fever. Following a risk-benefit assessment, it was recommended the exposed person take an experimental vaccine that had shown PEP efficacy in ZEBOV-infected nonhuman primates (NHPs) [12]. The vaccine, which had not been used previously in humans, was a live-attenuated recombinant vesicular stomatitis virus (recVSV) expressing the glycoprotein of ZEBOV. A single dose of 5 × 10 7 plaque-forming units was injected 48 hours after the accident. The vaccinee developed fever 12 hours later and recVSV viremia was detectable by polymerase chain reaction (PCR) for 2 days. Otherwise, the person remained healthy, and ZEBOV RNA, except for the glycoprotein gene expressed in the vaccine, was never detected in serum and peripheral blood mononuclear cells during the 3-week observation period.

UR - http://www.scopus.com/inward/record.url?scp=80054757055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054757055&partnerID=8YFLogxK

U2 - 10.1093/infdis/jir298

DO - 10.1093/infdis/jir298

M3 - Article

VL - 204

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - SUPPL. 3

ER -